Human Immunoglobulin Preparations

Restivo, Joseph S.A.; Karafin, Matthew S.

doi:10.1016/b978-0-12-813726-0.00039-8

Cited by 1 publication

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIG therapies are produced from plasma of a definite number of individuals with high titer of specific antibody against a microorganism. According to WHO/IUIS, HIG products should contain at least fivefold increased specific antibody titers compared with standard preparations of IVIG [17]. For the preparation of HIG, a new plasma pool collection is required to produce commercial HIG products as a time-span is needed for convalescence.…”

Section: Convalescent Plasma and Hyperimmunoglobulin Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Convalescent plasma and hyperimmune globulin therapy in COVID-19

Çağdaş

2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice. Medical literature is reviewed for randomized controlled studies using convalescent plasma therapy. Areas covered: More than one type of neutralizing antibody against a specific microorganism may be found in both CP and hyperimmune globulins. To give a standard titer of a specific neutralizing antibody to a patient, a reliable antibody titration assay should be developed. It is challenging to test the efficacy of the CP and HIG therapies with double-blind studies. There is a difficulty in the standardization of the CP and HIG study groups, as patients use various additional therapies. Different amounts and titers of CP and HIG and different titers of CP are used in patients. This review discusses the current knowledge on CP and HIG therapies used in COVID-19 disease. Expert opinion: The immune response to COVID-19 have diverse characteristics. The antibody produced after COVID-19 disease and vaccination is short-lived. Thus, CP should be an alternative especially in patients with lymphopenia and primary/secondary antibody deficiency.

show abstract

Section: Convalescent Plasma and Hyperimmunoglobulin Therapiesmentioning

confidence: 99%

“…Immunoglobulin products are prepared from large pools (obtained from a minimum of 10,000 donors) of whole blood or apheresis-derived plasma [17] (Figure 1). It has several effects on viral infections.…”

Section: Introductionmentioning

confidence: 99%

Convalescent plasma and hyperimmune globulin therapy in COVID-19

Çağdaş

2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

Human Immunoglobulin Preparations

Cited by 1 publication

References 4 publications

Convalescent plasma and hyperimmune globulin therapy in COVID-19

Convalescent plasma and hyperimmune globulin therapy in COVID-19

Contact Info

Product

Resources

About